Recent exceptional positive changes in investment behavior have benefitted Corcept Therapeutics Inc (NASDAQ: CORT): the stock rose on very heavy volume, and positive upside/downside volume developed.
Recent meaningful positive changes in fundamentals have benefitted Corcept Therapeutics Inc (NASDAQ: CORT): significant quarterly earnings acceleration occurred, and the consensus estimate for December, 2025 increased significantly.
In light of these very positive signals we are reviewing our current Overall Rating of C. We would view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
CORT is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
Corcept Therapeutics has a current Value Trend Rating of C (High Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Corcept Therapeutics has a poor Appreciation Score of 26 but a very high Power Rating of 99, producing the High Neutral Value Trend Rating.
Recent Price Action
Corcept Therapeutics Inc (NASDAQ: CORT) stock closed at $49.75 on 10/18/24 after a very large increase of 5.5%. Moreover, exceptionally high trading volume at 375% of normal accompanied the advance. The stock has risen 9.9% during the last week and has been exceptionally strong relative to the market over the last nine months.
Be the first to comment